Global benefit-risk analysis of adjunctive aripiprazole in the treatment of patients with major depressive disorder

Pharmacoepidemiology and Drug Safety

Volumn 18, Issue 10, 2009, Pages 965-972

  Wisniewski, Stephen R ^a   Chen, Chi Chang ^b   Kim, Edward ^b   Kan, Hong J ^b   Guo, Zhenchao ^b   Carlson, Berit X ^b   Tran, Quynh Van ^c   Pikalov, Andrei ^c  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

Aripiprazole; Clinical advantage; Major depressive disorder

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ESCITALOPRAM; FLUOXETINE; PAROXETINE; PLACEBO; SERTRALINE; VENLAFAXINE;

ADULT; AKATHISIA; ARTICLE; BLURRED VISION; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONOTHERAPY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; NAUSEA; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; RESTLESSNESS; RISK BENEFIT ANALYSIS; SCORING SYSTEM; SEX DIFFERENCE; SIDE EFFECT; SINGLE BLIND PROCEDURE; SOMNOLENCE; TREATMENT OUTCOME; TREMOR; URINARY TRACT INFECTION; WEIGHT GAIN; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; ODDS RATIO; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 70450205268     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1805     Document Type: Article

References (19)

1. Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 2003; 53: 649-659.
2. Papakostas GI, Shelton RC, Smith J, et al. Augmentation of antidepressants with atypical antipsychotic medications for treatmentresistant major depressive disorder: a meta-analysis. J Clin Psychiatry 2007; 68: 826-831. (Pubitemid 47015480)
3. Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007; 68: 843-853. (Pubitemid 47015482)
4. Marcus RN, McQuade RD, Carson WH, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2008; 28: 156-165.
5. Thase ME, Trivedi M, Nelson CJ, et al. Examining the efficacy of adjunctive aripiprazole in major depressive disorder: a pooled analysis of 2 studies. Prim Care Companion J Clin Psychiatry 2008; 10: 440-447.
6. Nelson JC, Thase ME, Trivedi MH, et al. Safety and tolerability of adjunctive aripiprazole in major depressive disorder: a pooled analysis (Studies CN138-139 and CN138-163). Prim Care Companion. J Clin Psychiatry 2009; in press.
7. Pritchett YL, Tamura R. Global benefit-risk assessment in designing clinical trials and some statistical considerations of the method. Pharm Stat 2008; 7: 170-178.
8. Perahia DG, Pritchett YL, Kajdasz DK, et al. A randomized, doubleblind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder. J Psychiatr Res 2008; 42: 22-34. (Pubitemid 47570043)
9. Entsuah R, Gao B. Global benefit-risk evaluation of antidepressant action: comparison of pooled data for venlafaxine, SSRIs, and placebo. CNS Spectr 2002; 7: 882-888. (Pubitemid 36765048)
10. Entsuah R, Gorman JM. Global benefit-risk assessment of antidepressants: venlafaxine XR and fluoxetine. J Psychiatr Res 2002; 36: 111-118. (Pubitemid 34218951)
11. Chuang-Stein C, Mohberg NR, Sinkula MS. Three measures for simultaneously evaluating benefits and risks using categorical data from clinical trials. Stat Med 1991; 10: 1349-1359.
12. Patkar AA, Peindl K, Mago R, et al. An open-label, rater-blinded, augmentation study of aripiprazole in treatment-resistant depression. Prim Care Companion J Clin Psychiatry 2006; 8: 82-87. (Pubitemid 44371587)
13. Papakostas GI, Petersen TJ, Kinrys G, et al. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. J Clin Psychiatry 2005; 66: 1326-1330. (Pubitemid 41546514)
14. Pae CU, Patkar AA, Jun TY, et al. Aripiprazole augmentation for treatment of patients with inadequate antidepressants response. Depress Anxiety 2007; 24: 522-526. (Pubitemid 350086265)
15. Simon JS, Nemeroff CB. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder. J Clin Psychiatry 2005; 66: 1216-1220.
16. Worthington JJ 3rd, Kinrys G, Wygant LE, et al. Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients. Int Clin Psychopharmacol 2005; 20: 9-11.
17. Reimherr F, Martin M, Qi Y, et al. Adjunctive Aripiprazole Improves Core Depressive Symptoms:A Pooled Analysis of Montgomery Asberg Depression Rating Scale Items (CN138-139/-163). Presented at the American Psychiatry Association, Washington, May 3-8, 2008.
18. Fava M, Rush AJ. Current status of augmentation and combination treatments for major depressive disorder: a literature review and a proposal for a novel approach to improve practice. Psychother Psychosom 2006; 75: 139-153.
19. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163: 1905-1917.